Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $71

Piper Sandler analyst David Amsellem maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate

Futu NewsMay 23 19:33

Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating

Needham analyst Serge Belanger maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 42.8% and a total average return of 1.8%

Futu NewsMay 23 18:36

Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70

Capital One Financial analyst Tim Chiang maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success r

Futu NewsMay 23 14:31

Sector Update: Health Care Stocks Advance Wednesday Afternoon

Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) climbed 1

MT NewswiresMay 23 02:01

Amphastar Pharmaceuticals Holds Steady Amidst New Approval and Competitive Market

TipRanksMay 22 22:56

Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug

Amphastar Pharmaceuticals (AMPH) said Wednesday the US Food and Drug Administration has approved its Abbreviated New Drug Application for albuterol sulfate inhalation aerosol to treat bronchospasm in

MT NewswiresMay 22 22:17